Advertisement

Pharmacy

An off-the-shelf CAR-T cell therapy being developed by CRISPR Therapeutics saw positive results in some patients with advanced B-cell lymphoma, but was also tied to a patient's death, the drugmaker said Oct. 21. 

Kodak CEO Jim Continenza said the company still will make active pharmaceutical ingredients regardless of government assistance after its $765 million loan from the U.S. was stalled due to insider-trading allegations, The Wall Street Journal reported. 

Advertisement
Advertisement